STAT First Opinion: The life sciences industry needs a new approach

A narrow focus on biochemical solutions isn’t working

Click the image to view the full PDF of the article.

In this First Opinion piece in STAT, Luminous CEO & Principal Noël Theodosiou and Advisor, Yogi Hendlin address how developers and manufacturers of biopharmaceuticals and medical devices must step up to reduce the gap between healthcare spending and outcomes, and how we can challenge the industry to think differently.

The life sciences industry has a unique social contract with the public, given its role in developing and commercializing therapies and diagnostics, public funding granted for its trials, and guaranteed patent terms for its innovations.

Yet, despite great scientific innovation in the past decade, and high per capita expenditure on health, U.S. patients are struggling.

With clinical care accounting for – at most – 20% of health outcomes, and drugs and devices a small portion of that, it’s clear that the industry’s narrow focus on biochemical solutions has proven inadequate.

Full article on STAT: https://www.statnews.com/2025/02/10/life-sciences-biochemical-focus-maha-integrated-approaches/